Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Edison LS[original query] |
---|
Fentanyl-associated illness among substance users - Fulton County, Georgia, 2015
Angela Parham M , Pomerleau AC , Peralta G , Drenzek CL , Edison LS . Am J Emerg Med 2018 36 (11) 2115-2117 In early 2015, Hospital A emergency physicians subjectively noticed an increase in opioid overdoses presenting to the emergency department (ED) that corresponded with an increase in fentanyl-positive substance-related deaths documented by the Fulton County medical examiner (ME). This prompted Hospital A emergency physicians to begin selective fentanyl urine drug screening (UDS) for patients with clinical signs of opioid intoxication. After testing revealed that some patients had UDS positive for fentanyl, Hospital A began testing for fentanyl as part of all routine UDS in May 2015 and notified the Georgia Department of Public Health (DPH) of their findings. Fentanyl had not been commonly reported as associated with substance abuse and overdose in Georgia before this cluster. DPH initiated an epidemiologic investigation to characterize events and guide prevention efforts. |
Endophthalmitis outbreak associated with repackaged bevacizumab
Edison LS , Dishman HO , Tobin-D'Angelo MJ , Allen CR , Guh AY , Drenzek CL . Emerg Infect Dis 2015 21 (1) 171-3 An outbreak of endophthalmitis associated with repackaged bevacizumab occurred during February–March 2013 in Georgia and Indiana, USA. Bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA, USA) is a vascular endothelial growth factor inhibitor that is approved by the US Food and Drug Administration as an antineoplastic agent but is commonly used off-label to treat retinal disorders, including age-related macular degeneration (1,2). Bevacizumab is manufactured in single-use, preservative-free, 4-mL vials; compounding pharmacies repackage bevacizumab into syringes for intraocular administration at smaller doses (e.g., 1.25 mg bevacizumab in 0.05-mL injection). Repackaged bevacizumab has been linked to endophthalmitis outbreaks worldwide in which compounding procedure deficiencies have led to microbial contamination and subsequent endophthalmitis (3–7). Endophthalmitis often results in vision loss, particularly if the infection is not identified early and treated aggressively (4–6). | During March 6–8, 2013, four patients with age-related macular degeneration received a diagnosis of acute endophthalmitis after receiving intravitreal bevacizumab injections on March 4, 2013, at a retinal specialty clinic (clinic A) in Georgia. All 4 patients were injected with bevacizumab from the same lot (lot Z), which was repackaged at a Georgia compounding pharmacy (pharmacy A) on February 13, 2013. The Georgia Department of Public Health (DPH) and the Georgia Drug and Narcotics Agency (GDNA) were notified of the outbreak by clinic A, and the outbreak was investigated to determine the extent and source of infections and to prevent additional cases. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure